NCT07110038招募中2 期
DEPECA-1 - DEfeating PEnile Cancer 1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest8 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2025年12月16日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
- 试验地点
- 8
- 主要终点
- Objective Response Rate (ORR)
研究概览
简要总结
The DEPECA-1 trial is the first systematic Phase II trial to evaluate response and survival to a combination of antibody-drug conjugate enfortumab vedotin plus the PD-L1 inhibitor avelumab in patients with locally advanced and metastatic penile squamous cell carcinoma (PeCa) in the 1st line setting.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patient has ability to understand and the willingness to sign a written informed consent.
- •Patient is ≥ 18 years of age at time of signing the written informed consent.
- •Male patients with histologically confirmed diagnosis of penile squamous cell carcinoma.
- •Patients must be considered non-eligible for curative surgical management. Eligibility for trial inclusion should be based on the presence of either distant metastatic disease (M1) or at least one of the following scenarios based on the UICC/AJCC 8th edition TNM clinical and pathological classification of penile cancer:
- •Stage 3 (cT3) disease with a single lymph node involved (N1).
- •Stage 4 disease (cT4).
- •Any T stage with either N2 (involvement of multiple or bilateral inguinal nodes) or N3 (fixed inguinal nodal mass or pelvic lymphadenopathy) disease. Patients without distant metastases are eligible if multidisciplinary team review concludes that they are unsuitable for curative surgery.
- •Tumor material (archival or current) is available for local pathology testing (PD-L1, HPV).
- •Eastern Cooperative Oncology Group (ECOG) performance status of ≤
- •Measurable disease per RECIST 1.1 criteria.
- •No prior systemic therapy for metastatic or locally advanced PeCa in the palliative setting. NOTE: (Neo)adjuvant systemic therapy (without IO) is allowed at least 6 months before study enrollment.
- •Patients has adequate blood count, liver-enzymes, and renal function:
- •ANC (Absolute neutrophil count) > 1,500 cells/μL without the use of hematopoietic growth factors.
- •Platelet count ≥ 100 x 109/L (>100,000 per mm3).
- •Hemoglobin ≥ 9 g/dL.
- •Serum total bilirubin ≤ 1.5x institutional upper normal limit (ULN).
- •AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional ULN (or ≤ 5 x ULN if liver metastases are present).
- •Creatinine clearance ≥ 30 mL/min as calculated by the Cockcroft- Gault equation (or local institutional standard method).
- •No other active malignancy within the past 3 years, except for adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin.
- •No history of significant cardiovascular disease (e.g., myocardial infarction, unstable angina) within the last 6 months.
- •Life expectancy of at least 3 months.
- •Willingness to comply with study requirements, including follow-up visits and procedures.
- •Patients with female partners of childbearing potential must agree to use an effective method of contraception during the study and for 4 months after the last dose of enfortumab vedotin or for at least 30 days after last avelumab treatment administration, whichever occurs last.
排除标准
- •Previous systemic therapy for metastatic or locally advanced PeCa in the palliative setting.
- •Previous treatment with investigational drugs or devices within 30 days prior to the first dose of trial treatment.
- •Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- •Active, known, or suspected autoimmune disease requiring systemic treatment within the past 2 years. Patients with controlled autoimmune d disease not requiring systemic immunosuppressive treatment including diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases are eligible.
- •Has ongoing sensory or motor neuropathy Grade 2 or higher.
- •Has a history of uncontrolled diabetes (HbA1c > 8%).
- •Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.
- •Active infection requiring systemic therapy. The following exceptions apply:
- •Patients with an HIV infection are eligible if they are on effective antiretroviral therapy with undetectable viral load within 6 months, provided there is no expected drug-drug interaction.
- •Patients with evidence of chronic HBV infection are eligible if the HBV viral load is undetectable on suppressive therapy (if indicated), and if they have ALT, AST, and total bilirubin levels < ULN, and provided there is no expected drug-drug interaction.
- •Patients with a history of HCV infection are eligible if they have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load, and if they have ALT, AST, and total bilirubin levels < ULN.
- •History of other malignancies within the past 3 years, with the exception of adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin.
- •Severe hepatic impairment (Child-Pugh Class C).
- •Severe renal impairment or requirement for dialysis.
- •History of keratitis and corneal ulceration in the last two years.
- •Active pneumonia, pneumonitis or pulmonary fibrosis.
- •Active tuberculosis.
- •Known prior severe hypersensitivity to the study drugs or any component of their formulations, known severe hypersensitivity reactions to monoclonal antibodies (NCT CTCAE Grade ≥ 3).
- •Inability or unwillingness to comply with study requirements, including follow-up visits and procedures.
- •Inability to provide informed consent.
- •Use of immunosuppressive medication within 14 days prior to the first dose of study treatment, with the exception of intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection), systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent, or steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
- •Prior organ transplantation including allogenic stem-cell transplantation.
- •Vaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines.
- •Persisting toxicity related to prior therapy (NCI CTCAE Grade > 1); however, alopecia or other Grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable.
- •Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
- •Patient participated in another interventional clinical study according to Medicines Act within 28 days prior to study enrollment or participation in a clinical study according to Medicines Act at the same time as this study unless it is an observational / non-interventional study or during the follow- up period of an interventional study.
研究组 & 干预措施
Combined therapy consisting of enfortumab vedotin and avelumab
Experimental
干预措施: enfortumab vedotin (Drug)
Combined therapy consisting of enfortumab vedotin and avelumab
Experimental
干预措施: Avelumab (Drug)
结局指标
主要结局
Objective Response Rate (ORR)
时间窗: Up to 24 months.
Objective Response Rate (ORR) in 1st line as assessed by investigators, defined as the proportion of patients achieving a complete response (CR) or partial response (PR) according to RECIST 1.1 criteria.
次要结局
- Overall Survival (OS)(Up to 5 years.)
- Progression-free survival (PFS)(Up to 5 years.)
- Duration of Response (DoR)(Up to 5 years.)
- Disease Control Rate (DCR)(Up to 27 months.)
- Incidence and severity of (serious) adverse events(Up to 27 months)
- Quality of life (QoL) using EQ-5D-5L questionnaire(Up to 24 months.)
- Quality of life (QoL) using EQ-HWB-S questionnaire(Up to 24 months.)
研究者
研究点 (8)
Loading locations...
相似试验
尚未招募
2 期
A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.Gastric CancerNCT05594381The First Affiliated Hospital with Nanjing Medical University90
已完成
2 期
Immunotherapy in Patient With Poor General ConditionNon-small Cell Lung Cancer Stage IVNCT04108026Intergroupe Francophone de Cancerologie Thoracique50
招募中
2 期
Sintilimab Combined With Chidamide in Treating Peripheral T Cell LymphomaPeripheral T-cell LymphomaNCT04512534Fudan University51
尚未招募
2 期
Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction AdenocarcinomaAdenocarcinoma of the StomachAdenocarcinoma of Esophagogastric JunctionEpstein-Barr Virus-Associated Gastric CarcinomaNCT05970627Yu jiren30
Unknown
2 期
Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin LymphomaHodgkin LymphomaNCT04239170Peking University84